1st November 2001
PROACTA Therapeutics Limited a new company developing novel treatment modalities in cancer therapy
30th August 2001
Antisoma in-licenses DMXAA, a promising tumour blood vessel targeting agent in Phase I trials
5th June 2001
Cancer Research Ventures signs Exclusive Licence Agreement with Epigenomics AG, Berlin, Germany
April 2001
Qugen Therapeutics PTE. Ltd - a new gene therapy combining technologies from the UK and Singapore
5th April 2001
Biotech Research Ventures PTE. LTD is launched
24th January 2001
Cancer Research Campaign Technology appoints Cancer Research Ventures as Exclusive Agent
|
